Part 7/10:
Both Shannon and Michael speculated on the broader implications of this acquisition, indicating a shift in how large biopharma companies view potential buyouts. Rather than solely evaluating singular products, firms now consider the overall platforms, technological capabilities, and the potential for future drug development.